Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.125568

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

Patrizia Mondello, Elliott J. Brea, Elisa De Stanchina, Eneda Toska, Aaron Y. Chang, Myles Fennell, Venkatraman Seshan, Ralph Garippa, David A. Scheinberg, José Baselga, Hans-Guido Wendel, and Anas Younes

Find articles by Mondello, P. in: JCI | PubMed | Google Scholar

Find articles by Brea, E. in: JCI | PubMed | Google Scholar

Find articles by De Stanchina, E. in: JCI | PubMed | Google Scholar

Find articles by Toska, E. in: JCI | PubMed | Google Scholar

Find articles by Chang, A. in: JCI | PubMed | Google Scholar

Find articles by Fennell, M. in: JCI | PubMed | Google Scholar

Find articles by Seshan, V. in: JCI | PubMed | Google Scholar

Find articles by Garippa, R. in: JCI | PubMed | Google Scholar

Find articles by Scheinberg, D. in: JCI | PubMed | Google Scholar

Find articles by Baselga, J. in: JCI | PubMed | Google Scholar

Find articles by Wendel, H. in: JCI | PubMed | Google Scholar

Find articles by Younes, A. in: JCI | PubMed | Google Scholar

Published November 15, 2018 - More info

Published in Volume 3, Issue 22 on November 15, 2018
JCI Insight. 2018;3(22):e125568. https://doi.org/10.1172/jci.insight.125568.
Copyright © 2018, American Society for Clinical Investigation
Published November 15, 2018 - Version history
View PDF

Related article:

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Patrizia Mondello, … , Hans-Guido Wendel, Anas Younes
Patrizia Mondello, … , Hans-Guido Wendel, Anas Younes
Downregulation of MyD88 enhances ibrutinib efficacy in ABC DLBCL with L265P mutation by interrupting a newly discovered BCR signaling amplification loop involving NF-kB, STAT3, and MyD88.
Research Article Hematology Oncology

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

  • Text
  • PDF
Abstract

Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial and of a short duration. Here, we demonstrated that MyD88 silencing enhanced ibrutinib efficacy in DLBCL cells harboring MyD88 L265P mutations. Chemical downregulation of MyD88 expression with HDAC inhibitors also synergized with ibrutinib. We demonstrate that HDAC inhibitor regulation of MyD88 expression is mediated by STAT3. In turn, STAT3 silencing caused a decrease in MyD88 mRNA and protein levels, and enhanced the ibrutinib antilymphoma effect in MyD88 mutant DLBCL cells. Induced mutations in the STAT3 binding site in the MyD88 promotor region was associated with a decrease in MyD88 transcriptional activity. We also demonstrate that treatment with the HDAC inhibitor panobinostat decreased phosphorylated STAT3 binding to the MyD88 promotor. Accordingly, combined treatment with panobinostat and ibrutinib resulted in enhanced inhibition of NF-κB activity and caused regression of DLBCL xenografts. Our data provide a mechanistic rationale for combining HDAC inhibitors and ibrutinib for the treatment of DLBCL.

Authors

Patrizia Mondello, Elliott J. Brea, Elisa De Stanchina, Eneda Toska, Aaron Y. Chang, Myles Fennell, Venkatraman Seshan, Ralph Garippa, David A. Scheinberg, José Baselga, Hans-Guido Wendel, Anas Younes

×

Original citation: JCI Insight. 2017;2(6):1–14. https://doi.org/10.1172/jci.insight.90196

Citation for this corrigendum: JCI Insight. 2018;3(22):e125568. https://doi.org/10.1172/jci.insight.125568

David A. Scheinberg’s conflict-of-interest statement was not included in the manuscript. The correct statement is below.

DAS sits on boards for, was a consultant to, and/or owns stock or options in Sellas Life Sciences, Progenics Pharmaceuticals, Actinium Pharmaceuticals Inc., and Great Point Partners, companies that are not germane to the work in this paper. DAS owned stock in the following companies: Johnson & Johnson, Pfizer, and Abbott as well as DaVita, Intuitive Surgical, Edwards Lifesciences, Sapience Therapeutics, and ContraFect Corp.; these latter companies are not related to the work in this paper. DAS is an inventor on patents (US patent nos. 10,040,865, 9,976,137, 9,919,037, 9,289,519, 8,486,409, 6,156,316, 5,730,982, 6,603,127, 7,488,718, and 7,747,395) owned by Memorial Sloan Kettering Cancer Center and not germane to the work in this paper.

The authors regret the error.

Footnotes

See the related article at Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.

Version history
  • Version 1 (November 15, 2018): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts